Characteristics of melanoma cell lines
| Cell line | BRAF or NRAS mutational status | Other oncogenic events or tumor-suppressor deletions | Sensitive (S) or resistant (R) to vemurafeniba |
|---|---|---|---|
| M285 | Wild-type (36) | R | |
| M229 | BRAF V600E | MITF amplification | S (34, 35, 45) |
| AKT1 amplification | |||
| PTEN heterozygous | |||
| M233 | BRAF V600E | AKT1 amplification | R (35) |
| CCND1 amplification | |||
| EGFR amplification | |||
| CDKN2A heterozygous | |||
| PTEN heterozygous | |||
| M249 | BRAF V600E | MITF amplification | S (34, 35, 45) |
| AKT2 amplification | |||
| PTEN homozygous | |||
| M263 | BRAF V600E | CDKN2A heterozygous | R (34, 35) |
| M308 | BRAF V600E | MITF amplification | R (35) |
| AKT2 amplification | |||
| EGFR amplification | |||
| CDKN2A homozygous | |||
| M370 | BRAF V600E | R (34) | |
| M395 | BRAF V600E | S (34, 45) | |
| M417 | BRAF V600E | ABL1 E255K, Y253H | R |
| EGFR P753S | |||
| M202 | NRAS Q61L | EGFR amplification | R (35) |
| CDKN2A homozygous | |||
| M408 | NRAS Q61K | R | |
| M376 | BRAFV600E/NRAS Q61K | R (34) |
↵aSensitive, <1 μmol/L; resistant, >1 μmol/L.